SLC25A20 and metabolic syndrome: In this respect, in light of the role played by acylcarnitine accumulation in metabolic syndrome [60], the development of therapeutic strategies to regulate CACT activity might furnish valid approaches to the management of syndromes associated with altered fatty acid oxidation.